Biotech

Biotech & Healthcare News

Biotech Healthcare Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 30.05.2022.

#sciencenews
#ASCO2022
#AFM24
#340B
#MEDICAIDGP2022

Healthcare

@jonathanrockoff shared
On May 25, 2022
Enochian BioSciences co-founder Serhat Gumrukcu was arrested this week on charges he was involved in a murder-for-hire scheme, ⁦@joewalkerWSJ⁩ reports https://t.co/AGiPNgm3fj
Open
Biotech Founder Arrested in Murder-for-Hire Scheme

Biotech Founder Arrested in Murder-for-Hire Scheme

Serhat Gumrukcu, of Enochian BioSciences, was recently indicted in connection with the 2018 death of a Vermont man.

@SomercoResearch shared
On May 25, 2022
Research boosts 'game-changing' technology to strengthen drug development https://t.co/jr18yePrmP #sciencenews
Open
Research boosts 'game-changing' technology to strengthen drug development

Research boosts 'game-changing' technology to strengthen drug development

Researchers have boosted pioneering technology to show whether potential treatments are worth progressing into human trials, in a game-changing move that could dramatically reduce the high ...

@BIODeutschland shared
On May 27, 2022
RT @affimed: #ASCO2022 is just around the corner, and we’ll be sharing lots of #AFM24 news with you. Come meet us at the poster session on June 5th, we look forward to presenting and discussing our ongoing trial designs. To learn more, follow this link: https://t.co/yX4855m53y https://t.co/aOpUxoR0Ck
Open
Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

Design and rationale of the phase 1/2a open label, multicenter study of the AFM24 monotherapy in patients with advanced EGFR-expressing solid tumors Design and rationale of the …

@bengoldacre shared
On May 27, 2022
NEW @OpenSAFELY paper KLAXON Comparing sotrovimab and molnupiravir for prevention of severe outcomes in non-hospitalised patients with COVID-19. https://t.co/bfVVEpMes7 Preprint not yet peer reviewed, under review at a journal, sharing for info. INTERESTING THINGS THREAD: 1/n
Open
Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe COVID-19 outcomes in non-hospitalised patients: an observational cohort study using the OpenSAFELY platform

Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe COVID-19 outcomes in non-hospitalised patients: an observational cohort study using the OpenSAFELY platform

Objective: To compare the effectiveness of sotrovimab (a neutralising monoclonal antibody) vs. molnupiravir (an antiviral) in preventing severe COVID-19 outcomes in non-hospitalised ...

@DeloitteHealth shared
On May 24, 2022
Attending the Medicaid & Government Pricing Congress this week? On Wed, don't miss Deloitte's Marcy Imada as she discusses #340B compliance requirements and HRSA integrity initiatives. #MEDICAIDGP2022 https://t.co/TcBUFMk039
Open
The Medicaid and Government Pricing Congress takes you inside health policy with 26 hours of content to learn and 30 days of access to execute

The Medicaid and Government Pricing Congress takes you inside health policy with 26 hours of content to learn and 30 days of access to execute

The Medicaid and Government Pricing Congress takes you inside health policy with 26 hours of content to learn and 30 days of access to execute Government Pricing Experts Simplify Medicaid ...